

Assignment of Patents

Dated: 07.02.2020, 2020

Parties

- (1) **Zealand Pharma A/S**, a public limited liability company registered under the laws of Denmark under company registration no. (CVR) 20 04 50 78, having its address at Sydmarken 11, DK-2860 Søborg, Denmark ("**the Assignor**")

and
- (2) **ZP SPV 3 K/S**, a limited partnership incorporated under the laws of Denmark under company registration no. (CVR) 41 03 80 39, having its address at Sydmarken 11, DK-2860 Søborg, Denmark ("**the Assignee**")

Agreed terms

1. Definition

The following definitions and rules of interpretation apply in this Assignment.

Assigned Rights means the Patents and all the Intellectual Property Rights therein.

Intellectual Property Rights means the patents, rights to inventions and all other intellectual property rights, and including all applications and rights to apply for and be granted, renewals or extensions of, and rights to claim priority from, such rights and all similar or equivalent rights or forms of protection which subsist or will subsist now or in the future in any part of the world.

Patents means the patents and patent applications, short particulars of which are set out in Schedule 1.

2. Assignment

For good and valuable consideration (receipt and sufficiency of which the Assignor expressly acknowledges), the Assignor hereby assigns to the Assignee absolutely all its right, title and interest in and to the Assigned Rights including (but not limited to):

- (a) The Patents;
- (b) The right to bring, make, oppose, defend, appeal proceedings, claims or actions and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action arising from ownership, of any of the Assigned Rights whether occurring before, on, or after the date of this Assignment.

3. Further assurance

Each party shall, and shall use all reasonable endeavours to procure that any necessary third party shall, execute such documents and perform such acts as may be required for the purpose of giving full effect to this Assignment.

4. Counterparts

This Assignment may be executed in any number of counterparts, each of which when executed shall constitute a duplicate original, but all the counterparts shall together constitute the one agreement. No counterpart shall be effective until each party has executed at least one counterpart.

This Assignment has been entered into on the date stated at the beginning of it.

Assignment of Patents

Dated: 07.02.2020, 2020

Parties

- (1) **Zealand Pharma A/S**, a public limited liability company registered under the laws of Denmark under company registration no. (CVR) 20 04 50 78, having its address at Sydmarken 11, DK-2860 Søborg, Denmark ("**the Assignor**")
- and
- (2) **ZP SPV 3 K/S**, a limited partnership incorporated under the laws of Denmark under company registration no. (CVR) 41 03 80 39, having its address at Sydmarken 11, DK-2860 Søborg, Denmark ("**the Assignee**")

Agreed terms

1. Definition

The following definitions and rules of interpretation apply in this Assignment.

Assigned Rights means the Patents and all the Intellectual Property Rights therein.

Intellectual Property Rights means the patents, rights to inventions and all other intellectual property rights, and including all applications and rights to apply for and be granted, renewals or extensions of, and rights to claim priority from, such rights and all similar or equivalent rights or forms of protection which subsist or will subsist now or in the future in any part of the world.

Patents means the patents and patent applications, short particulars of which are set out in Schedule 1.

2. Assignment

For good and valuable consideration (receipt and sufficiency of which the Assignor expressly acknowledges), the Assignor hereby assigns to the Assignee absolutely all its right, title and interest in and to the Assigned Rights including (but not limited to):

- (a) The Patents;
- (b) The right to bring, make, oppose, defend, appeal proceedings, claims or actions and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action arising from ownership, of any of the Assigned Rights whether occurring before, on, or after the date of this Assignment.

3. Further assurance

Each party shall, and shall use all reasonable endeavours to procure that any necessary third party shall, execute such documents and perform such acts as may be required for the purpose of giving full effect to this Assignment.

4. Counterparts

This Assignment may be executed in any number of counterparts, each of which when executed shall constitute a duplicate original, but all the counterparts shall together constitute the one agreement. No counterpart shall be effective until each party has executed at least one counterpart.

This Assignment has been entered into on the date stated at the beginning of it.

2. Assignment

For good and valuable consideration (receipt and sufficiency of which the Assignor expressly acknowledges), the Assignor hereby assigns to the Assignee absolutely all its right, title and interest in and to the Assigned Rights including (but not limited to):

- (a) The Patents;
- (b) The right to bring, make, oppose, defend, appeal proceedings, claims or actions and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action arising from ownership, of any of the Assigned Rights whether occurring before, on, or after the date of this Assignment.

3. Further assurance

Each party shall, and shall use all reasonable endeavours to procure that any necessary third party shall, execute such documents and perform such acts as may be required for the purpose of giving full effect to this Assignment.

4. Counterparts

This Assignment may be executed in any number of counterparts, each of which when executed shall constitute a duplicate original, but all the counterparts shall together constitute the one agreement. No counterpart shall be effective until each party has executed at least one counterpart.


This Assignment has been entered into on the date stated at the beginning of it.

Schedule 1: Patents

Country/ Region	Application No.	Filing Date	Title
Europe	18158834.4	27 February 2018	COMPSTATIN ANALOGUES AND THEIR MEDICAL USES
Europe	18214949.2	20 December 2018	COMPSTATIN ANALOGUES AND THEIR MEDICAL USES
PCT	PCT/EP2019/054685	26 February 2019	COMPSTATIN ANALOGUES AND THEIR MEDICAL USES
Taiwan	108106905	27 February 2019	COMPSTATIN ANALOGUES AND THEIR MEDICAL USES
Europe	19193924.8	27 August 2019	INHIBITORS OF COMPLEMENT FACTOR C3 AND THEIR MEDICAL USES
Europe	19193925.5	27 August 2019	COMPSTATIN ANALOGUES AND THEIR MEDICAL USES

AS WITNESS this Assignment has been signed by the duly authorised representatives of the Parties the day and year first written above.

For and on behalf of **Zealand Pharma A/S**:




Name: E. D. Vlac
Title: CEO

Name:
Title:

For and on behalf of **ZP SPV 3 K/S**:

By ZP General Partner 3 ApS in its capacity as general partner of ZP SPV 3 K/S




Name: E. D. Vlac
Title: Executive Manager

Name:
Title: Executive Manager

AS WITNESS this Assignment has been signed by the duly authorised representatives of the Parties the day and year first written above.

For and on behalf of **Zealand Pharma A/S**:




Name: E. D. Vlac
Title: CEO

Name:
Title:

For and on behalf of **ZP SPV 3 K/S**:

By ZP General Partner 3 ApS in its capacity as general partner of ZP SPV 3 K/S



Name: E. D. Vlac
Title: Executive Manager

Name:
Title: Executive Manager

AS WITNESS this Assignment has been signed by the duly authorised representatives of the Parties the day and year first written above.

For and on behalf of **Zealand Pharma A/S**:

Name:

Title:


Name: MATTHEW DAULT


Title: CEO

For and on behalf of **ZP SPV 3 K/S**:

By ZP General Partner 3 ApS in its capacity as general partner of ZP SPV 3 K/S

Name:

Title: Executive Manager


Name: MATTHEW DAULT

Title: Executive Manager